SR-17018, Friend or Foe?
- Harold Pierre, MD
- 5 hours ago
- 15 min read
SR-17018: Street Drug Threat or Safer Opioid Alternative?
Recently, I've been inundated with questions about SR-17018. I had read about this molecule years ago and tossed it from my memory. But now that it's available online and my patients are asking about it, it's time to re-examine this substance and share my findings.
SR-17018 has no FDA indication and no completed human clinical trial. And yet, as of 2026, you can buy it online for about $50 a gram, Reddit threads are walking people through opioid withdrawal protocols using it, and federal forensic labs are scrambling to develop testing methods that can even detect it. Like kratom before it, I am seeing a rapid rise in patient inquiry and I know what happens next. Experimental stage and then the consequences.
A drug moving from a university research paper to a gray-market research chemical in four years isn't unusual in the world of novel psychoactive substances. What makes SR-17018 different is the science behind it, at least what we know right now. It was designed as a potential analgesic for acute and chronic pain, built around a theory that this opioid might be safer for pain management. The pharmacology is genuinely interesting, and also genuinely incomplete, and both of those things matter a great deal for where this compound is headed. Especially since it is already in the streets.
What SR-17018 Actually Is
SR-17018 belongs to a chemical family called benzimidazolones, sometimes called "orphines." It's a mu opioid receptor agonist, meaning it binds the same receptor as morphine, fentanyl, oxycodone, hydrocodone, hydromorphone and buprenorphine. What sets it apart is how it activates that receptor.
When the mu opioid receptor fires, it sends signals down two separate signaling pathways. The first one, the G protein pathway, is what produces pain relief, sedation and the rewarding effects that make opioids both useful and addictive. The second one, the beta-arrestin2 pathway, is what drives tolerance, physical dependence, breathing suppression and constipation. That second pathway is behind most opioid overdose deaths. It's also why long-term opioid use becomes so hard to manage.
The biased agonism idea rests on a simple premise. Activate the G protein pathway while mostly ignoring the second one. If you can do that, you get the pain relief and withdrawal suppression without the side effects that kill people. Unlike conventional opioids that hit both pathways indiscriminately, a well-designed G-protein biased ligand would preferentially drive the pathway you want.
SR-17018 was built around that idea. It's technically a partial agonist at the mu opioid receptor, meaning it doesn't produce the full ceiling response that full agonists like DAMGO, the gold-standard reference compound in opioid receptor assays, reliably generate. Early lab tests showed it strongly drove G protein activation while barely touching the beta-arrestin2 pathway. Mouse studies showed pain relief, prevention of withdrawal and reduced tolerance in one widely used pain test. Those early results earned serious scientific attention.
Why Researchers Got Excited
Before getting into what the more recent data showed, the biased agonism theory deserves a fair hearing, because it was built on solid experimental science and not wishful thinking.
Scientists studied mice that were genetically modified to lack the beta-arrestin2 gene entirely. Those mice got stronger pain relief from morphine, with less breathing suppression and slower tolerance buildup. That opened a door. If a drug could produce that same effect chemically, you might have a genuinely safer opioid analgesic. Earlier work by Christie and colleagues had shown that beta-arrestin2 knockout prevents development of cellular mu opioid receptor tolerance but doesn't affect opioid-withdrawal-related adaptations equally, meaning the pathways governing tolerance and dependence are not fully overlapping, and a selective compound might exploit that gap.
In 2017, Schmid and colleagues published a landmark paper in Cell demonstrating that bias factor correlates directly with an improved therapeutic window. Their finding: the search for safer opioid analgesics wasn't wishful thinking; it had a measurable molecular basis.
A 2020 paper in Science Signaling by Gillis, Gondin, Kliewer, Sanchez, Lim, Alamein and Christie added another layer of evidence. They argued that low intrinsic efficacy for G protein activation could explain the improved side effect profiles of new opioid agonists, effects such as respiratory depression, constipation and tolerance, though they also cautioned that the relationship between biased signaling and clinical outcomes was more complex than early models predicted.
That same year, Grim, Schmid, Stahl, Pantouli, Acevedo-Canabal and Bohn published a study in Neuropsychopharmacology showing that a G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal. SR-17018 was that compound. The finding was striking: not only did it avoid generating tolerance, it seemed to undo tolerance that had already built up, pointing to a mechanism that went beyond simple receptor avoidance.
TRV130 (Brand name Olinvyk), also known as oliceridine, was the first drug built on this idea to reach human clinical trials. The FDA approved it in 2020 for acute pain in hospital settings. The benefit was real but smaller than the animal studies suggested. Respiratory depression was reduced compared to morphine at equivalent pain-relieving doses, but not eliminated.
SR-17018 was a later attempt with a stronger bias toward the G protein pathway. On paper, it looked like it might do better than oliceridine.
What Three Research Papers Actually Found
The scientific story of SR-17018 became considerably more complicated in 2021, when three papers published in the same year each revealed a different layer of complexity that the original characterization had missed.
SR-17018's Unusual Receptor Mechanism
Stahl, Schmid, Acevedo-Canabal, Read, Grim, Kennedy, Bannister and Bohn at Scripps Research published the most detailed study of SR-17018 to date in PNAS in November 2021. Their main finding: SR-17018 doesn't attach to the opioid receptor the way most opioids do. Most opioids compete directly for the same docking site on the mu opioid receptor. SR-17018 doesn't. It's what researchers call a noncompetitive agonist. It binds through a distinct allosteric (binding location) site and locks the receptor into an active G protein signaling state.
In their GTPγS binding assay, DAMGO behaved predictably, it activated the receptor, the receptor desensitized in the usual pattern, and G protein activation dropped over time. SR-17018 did not follow that path. The Scripps group demonstrated that G protein signaling-biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists. The receptor stayed active even after extensive washing removed all detectable drug from the preparation. The G protein was still firing.
That state persists even after the drug is cleared from the body. The researchers called it "wash-resistant." The receptor keeps firing long after the drug is gone. In vivo, this translated to unusually prolonged analgesic effects and an altered relationship with tolerance, because the receptor never truly saw a drug-free interval.
Naloxone does reverse this, which is reassuring from an overdose standpoint. But the reversal works differently than with standard opioids, it acts on the orthosteric (common location) binding site while SR-17018 occupies an allosteric site, and the cooperativity between those two sites actually makes naloxone more potent in that specific context. The Scripps group also filed a patent on the SR compounds, which suggests they see real development potential here.
Tolerance Depends on Which Pain Model You Use
Pantouli, Grim, Schmid, Acevedo-Canabal, Kennedy, Cameron, Bannister and Bohn published in Neuropharmacology in 2021. This comparison of morphine, oxycodone and the biased MOR agonist SR-17018 covered four different pain models in mice, using twice-daily dosing for six days.
In the hot-plate test, a supraspinal thermal pain reflex, SR-17018 produced no tolerance, confirming what earlier studies had reported. Morphine and oxycodone both did produce tolerance, as expected. But in the warm water tail immersion test, a spinal thermal reflex measuring a closely related process, SR-17018 produced tolerance comparable in magnitude to both morphine and oxycodone. Like morphine, it showed a significant rightward shift in potency with repeated dosing. The hot-plate advantage didn't transfer.
Where SR-17018 genuinely stood out was in inflammatory and neuropathic pain models. In the formalin test, it retained full efficacy with repeated dosing while oxycodone showed reduced efficacy and eventually lost it entirely. In the paclitaxel-induced peripheral neuropathy model, used to simulate chemotherapy-induced nerve pain and one of the more intractable chronic pain treatment challenges in palliative medicine, SR-17018 was more potent and more effective than both morphine and oxycodone, and it maintained that advantage over time while the other compounds faded.
The authors concluded that "a single nociceptive testing paradigm in rodents may be inadequate to define a compound's tolerance liability." The clean "no tolerance" story that had circulated was based on a single assay. The fuller picture is considerably more conditional.
The Biased Agonist Label Is Probably Wrong
The most unsettling data came from Fritzwanker, Schulz and Kliewer at Jena University Hospital in Germany. They looked at a molecular process called receptor phosphorylation. Think of it as the switch that decides whether beta-arrestin gets called in. Biased agonists are supposed to keep that switch mostly off. That's their whole advantage.
In the first ten minutes, SR-17018 behaved as expected. Minimal phosphorylation. Switch mostly off. So far, consistent with the biased agonist label.
After 20 to 60 minutes, the picture changed entirely. SR-17018 flipped that switch all the way over, matching the phosphorylation pattern of full agonists, specifically DAMGO, the reference compound used in the assay. The authors described this as "indistinguishable" from a standard full agonist. That alone puts the biased agonist theory in serious doubt for any real-world use scenario.
There was another layer to this. In full agonists, receptor internalization, the process by which the activated receptor is pulled off the cell surface, follows phosphorylation predictably. Buprenorphine produces no detectable internalization. SR-17018 drove robust receptor internalization comparable to DAMGO. The receptor was behaving like it had been fully activated by a conventional opioid, not by something designed to avoid those downstream effects.
What happened after the drug was cleared was even more surprising. With a standard full opioid, those phosphorylation switches reset within five to ten minutes. With SR-17018, they stayed on for hours. The receptor kept acting as if the drug were still there.
The most likely explanation is that SR-17018 simply doesn't let go. It clings to the receptor for an unusually long time. Standard lab tests for biased agonists use short time windows and never saw this coming. But in real use, a dose that stays bound for hours has plenty of time to flip every switch the researchers thought it was skipping.
The safety claims for SR-17018 were based on short-exposure experiments. They don't reflect what happens when someone actually uses the drug.
It's Already in the Gray Market
The National Drug Early Warning System (NDEWS) issued a formal surveillance alert on SR-17018 on November 14, 2025. Reddit monitoring data showed near-zero posts from early 2024, rising sharply to roughly 40 posts per 60-day monitoring window by October 2024, continuing upward through late 2025.
The Center for Forensic Science Research and Education (CFSRE) confirmed the first US forensic detections in the Mid-Atlantic region in Q4 2025 and issued its own alert on January 30, 2026. SR-17018 doesn't appear on standard drug screening panels. Identifying it requires LC-MS or GC-MS analysis. Most hospital toxicology labs running routine 10-panel or 15-panel screens will miss it entirely, which creates a significant clinical problem when someone presents in overdose.
Google Trends data shows the trajectory plainly. Zero search interest from May 2021 through February 2025. A first signal in March 2025. Then a peak of 100 out of 100 (maximum relative interest) during the week of March 7, 2026, with a reading of 73 out of 100 as of mid-May 2026. Something changed in people's awareness of this compound over roughly the past 14 months, and the trend line points up.
Gray-market vendors are selling SR-17018 openly under the "research chemical" label at prices around $30 to $50 per gram. It's not on the DEA's controlled substances list. The Federal Analogue Act could theoretically apply if intent to consume can be demonstrated, but enforcement is inconsistent.
Reddit discussions paint a clear picture of who's using it and why. People aren't describing recreational use. They're describing opioid withdrawal management. Detailed tapering protocols, dose calibration, comparisons to buprenorphine's profile, questions about detection windows. Some threads describe combining it with benzodiazepines, gabapentin or ketamine, which introduces separate overdose risks. This is a population that's self-medicating because they're not accessing formal treatment, or can't access it.
SR-17018's Dangerous Relatives
SR-17018 doesn't exist in isolation. The benzimidazolone chemical class includes brorphine, chlorphine, cychlorphine, fluorophine and at least seven other active analogs. As of 2026, eleven orphine analogs have been detected in fourteen countries and formally reported to the UNODC. Nine of those eleven appeared between 2024 and 2025.
Brorphine is the closest historical precedent. It appeared on European streets in 2019, reached the US in 2020 and was linked to somewhere between 21 and 120 or more US deaths before the DEA gave it an emergency Schedule I classification in March 2021 and permanent scheduling in 2022. Brorphine was more potent than fentanyl and showed up in illicit supplies sold as "purple heroin."
Cychlorphine is the current active concern. Estimates put its potency at 50 to 200 times stronger than heroin. As of late 2025, it has been linked to 78 fatal overdoses across 10 countries, including three deaths in London in October and November 2025. The UNODC issued alerts on novel orphine analogs in May 2025, February 2026 and May 2026. The UK's Advisory Council on the Misuse of Drugs recommended Class A scheduling for the entire orphine class in May 2026. Germany added orphines to its NpSG control framework in late 2025.
The global surge in orphine analogs has a direct cause. China enacted a blanket ban on nitazene analogs in July 2025. Street chemists switched to orphines as an alternative.
For someone buyin SR-17018 from a gray-market website, you don't know what you are getting. They have no way to verify the identity or purity of what they're receiving. The same supply chains that distribute SR-17018 are connected to networks producing compounds that are an order of magnitude or two more dangerous.
Will Naloxone Work?
For SR-17018 specifically, the available data is reassuring. The Bohn lab found that a low dose of naloxone fully reversed the breathing suppression caused by a closely related compound, SR-14968. A separate study confirmed that naloxone resets the receptor switches that SR-17018 leaves stuck in the on position. That effect doesn't happen with buprenorphine, which is one of several ways SR-17018 avoids the pharmacological profile of high-affinity partial agonists. Based on the available data, SR-17018 appears to be naloxone-reversible.
But a 2024 laboratory study examining the broader orphine class found that naloxone did NOT reverse respiratory depression from fluorophine, chlorphine and brorphine. These are SR-17018's chemical relatives.
If a first responder administers naloxone for what they believe is an SR-17018 overdose and the product was actually or partially a more potent orphine analog, standard naloxone dosing may fail entirely. The supply chain contamination problem makes this a real clinical scenario, not a theoretical one. Standard fentanyl test strips and nitazene test strips do not detect orphines, so point-of-care identification isn't available to either the user or the first responder.
What SR-17018 Means for Opioid Addiction Treatment
SR-17018 isn't a replacement for buprenorphine or methadone, not now and possibly not for a long time. There are no human studies and no abuse liability assessments. The biased agonism concept is still scientifically sound, but SR-17018 itself turned out to be far more complex than the early papers suggested. The early safety claims were based on short-exposure lab tests that missed the most important parts of how this drug actually behaves. Its profile in preclinical models is genuinely differentiated compared to morphine and oxycodone, but preclinical is where the story ends for now.
The more immediate clinical reality is that people are using a forensically undetectable, unscheduled research chemical to self-manage opioid addiction right now, today. Some are doing it because treatment access is genuinely broken in their area. Others have read the scientific papers online and found something that sounds credible. For a third group, the appeal is simply that a gray-market research chemical requires no prescription and no provider visit in ways that regulated medications do.
That's a treatment access problem. Researchers should keep developing biased agonism candidates, and the neuropathic chronic pain data for SR-17018 in particular suggests there's something worth developing properly. It may be useful for opioid pain management in ways that conventional opioids are not, particularly in neuropathic and inflammatory models where the development of tolerance typically destroys long-term efficacy. But the current situation, where patients are self-experimenting with a research chemical surrounded by orphine analogs that have been killing people across three continents, is not a solution.
Buprenorphine has real limitations. Ceiling effects, diversion concerns, patient compliance challenges. Methadone has its own serious risks. There's genuine unmet need in opioid addiction treatment for agents with different profiles. SR-17018 represents an interesting proof of concept toward that goal. Activation of opioid receptors through a truly biased mechanism remains one of the most credible strategies for getting there.
What it is right now is a wild-card compound in an unregulated supply chain, surrounded by chemical relatives that belong among the most dangerous synthetic opioids reported in recent years. Those two things can both be true at once. As an addiction medicine specialist with 26 years of experience in the field, I say don't try SR-17018 until it receives FDA approval and a physician evaluates you for treatment. That's a much safer option!
Frequently Asked Questions
Is SR-17018 legal in the United States?
SR-17018 is not currently listed as a controlled substance by the DEA. It's sold openly by gray-market "research chemical" vendors online. The Federal Analogue Act (21 U.S.C. § 813) could apply if a vendor or buyer intends it for human consumption, since it's structurally related to Schedule I mu-opioid receptor agonists, but this provision is inconsistently enforced. Germany added the orphine class to its NpSG controlled substances framework in late 2025. The UK's ACMD recommended Class A scheduling for orphines in May 2026. US scheduling may follow as detection data continues to accumulate.
Can naloxone reverse an SR-17018 overdose?
Based on available preclinical data, SR-17018 itself appears to be naloxone-reversible. A 2021 PNAS study from Scripps Research found that low-dose naloxone fully reversed respiratory suppression from a closely related compound in the same series. The concern is that gray-market products sold as SR-17018 may contain more potent orphine analogs such as cychlorphine or chlorphine, and a 2024 laboratory study found that naloxone did NOT reverse the respiratory depressant effects of those compounds. If you're responding to an overdose involving an unknown orphine, use naloxone as early and aggressively as possible, and treat any incomplete response as a medical emergency requiring immediate escalation.
How does SR-17018 compare to buprenorphine for opioid withdrawal management?
They're different in almost every pharmacological respect. Buprenorphine is a high-affinity partial agonist with a well-defined ceiling effect, 25+ years of clinical safety data and FDA-approved formulations. SR-17018 is a research compound with no human data, no standardized dosing and a complex receptor interaction profile that persists for hours after dosing. Users on Reddit have drawn comparisons based on both compounds' slow offset kinetics and withdrawal-suppressing properties, but that's a surface-level pharmacological comparison being applied in a completely uncontrolled context. The risks are not comparable. Buprenorphine has a known safety profile. SR-17018 does not.
What is a G protein-biased opioid agonist and why does it matter?
When an opioid binds the mu opioid receptor, it activates two internal pathways. The G protein pathway produces pain relief and the rewarding feeling opioids are known for. The beta-arrestin2 pathway drives tolerance, breathing problems and constipation. A G protein-biased agonist at the μ-opioid receptor tries to turn on the first pathway while leaving the second one mostly alone. The goal is effective pain relief or withdrawal management with less risk of overdose and slower development of tolerance. Oliceridine (Olinvyk) was the first drug in this class to get FDA approval, in 2020. It worked, but the safety advantage was smaller than animal studies predicted. SR-17018 was designed to do better, but later research found its mechanism is more complicated than the original biased agonist model.
References
Stahl EL, Schmid CL, Acevedo-Canabal A, Read C, Grim TW, Kennedy NM, Bannister TD, Bohn LM. G protein signaling-biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists. Proc Natl Acad Sci USA. 2021;118(48):e2102178118. doi: 10.1073/pnas.2102178118. PMID: 34819362. PMCID: PMC8640941.
Pantouli F, Grim TW, Schmid CL, Acevedo-Canabal A, Kennedy NM, Cameron MD, Bannister TD, Bohn LM. Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain. Neuropharmacology. 2021;185:108439. doi: 10.1016/j.neuropharm.2020.108439. PMID: 33345829. PMCID: PMC7887086.
Fritzwanker S, Schulz S, Kliewer A. SR-17018 stimulates atypical µ-opioid receptor phosphorylation and dephosphorylation. Molecules. 2021;26(15):4509. doi: 10.3390/molecules26154509. PMID: 34361663. PMCID: PMC8348759.
Grim TW, Schmid CL, Stahl EL, Pantouli F, Ho JH, Acevedo-Canabal A, Kennedy NM, Cameron MD, Bannister TD, Bohn LM. A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal. Neuropsychopharmacology. 2020;45:416–425. doi: 10.1038/s41386-019-0491-8. PMID: 31443104. PMCID: PMC6901606.
Gillis A, Gondin AB, Kliewer A, Sanchez J, Lim HD, Alamein C, Manandhar P, Santiago M, Fritzwanker S, Schmiedel F, Katte TA, Reekie T, Grimsey NL, Kassiou M, Kellam B, Krasel C, Halls ML, Connor M, Lane JR, Schulz S, Christie MJ, Canals M. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci Signal. 2020;13(625):eaaz3140. doi: 10.1126/scisignal.aaz3140. PMID: 32234959.
Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, Morgenweck J, Cameron MD, Bannister TD, Bohn LM. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. 2017;171(5):1165–1175.e13. doi: 10.1016/j.cell.2017.10.035. PMID: 29149605. PMCID: PMC5693250.
National Drug Early Warning System (NDEWS). Sentinel Community Site Surveillance Alert: SR-17018. November 14, 2025.
Center for Forensic Science Research and Education (CFSRE). Emerging Drug Alert: SR-17018 Detected in the United States. January 30, 2026.
United Nations Office on Drugs and Crime (UNODC). Global SMART Update: Emergence of Novel Benzimidazolone (Orphine) Opioids. May 2025, February 2026 and May 2026.
Advisory Council on the Misuse of Drugs (ACMD). Novel Synthetic Opioids: Seventh Addendum, Benzimidazolone Analogs. United Kingdom. May 2026.
Drug Enforcement Administration (DEA). Schedules of Controlled Substances: Placement of Brorphine in Schedule I. Federal Register. March 2021 (emergency scheduling) and 2022 (permanent scheduling).
Colombo Plan Drug Advisory Programme. Early Warning Advisory: Orphine-Class Synthetic Opioids. February 2026.
About the Author
Dr. Harold Pierre is a board-certified addiction medicine specialist and anesthesiologist with more than 26 years of clinical experience. He is licensed in Oklahoma, Texas, Arizona, Louisiana and Florida, and sees patients at his Tulsa-area practice seven days a week. Dr. Pierre provides both in-person and telehealth addiction medicine services, including medication-assisted treatment for opioid use disorder.
Connect with Dr. Pierre on LinkedIn or visit frugaldoctor.com to learn more.
Tulsa-area patients can call or text 918-518-1636 to schedule an appointment.
Disclaimer
This blog post is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis or treatment. Always seek the guidance of your doctor or other qualified health provider with any questions you may have regarding your health or a medical condition. Do not disregard professional medical advice or delay seeking it because of something you have read here.
If you or someone you know is struggling with opioid use disorder, please reach out to a qualified addiction medicine provider. Telehealth appointments are available for patients in Oklahoma, Texas, Arizona, Louisiana and Florida. Call or text 918-518-1636 or visit frugaldoctor.com.
Comments